HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Infiltrating duct carcinoma of breast — Clinical Guidelines

Overview

Infiltrating duct carcinoma (IDC), also known as infiltrating ductal carcinoma, is the most common histological subtype of breast cancer, accounting for approximately 75-80% of all breast cancer diagnoses 1 18. This aggressive form of breast cancer originates in the ductal cells of the breast and invades surrounding tissues, potentially leading to metastasis if left untreated. IDC significantly impacts patient outcomes, influencing survival rates and necessitating comprehensive treatment strategies including surgery, radiation, chemotherapy, and hormonal therapy. Given its prevalence and severity, accurate diagnosis and tailored management are crucial in day-to-day clinical practice to optimize patient outcomes and quality of life.

Pathophysiology

Infiltrating duct carcinoma develops through a series of genetic and molecular alterations that disrupt normal cellular functions, leading to uncontrolled proliferation and invasion. Key molecular pathways include dysregulation of cell cycle control, often mediated by mutations in genes such as TP53 and HER2 7. Oncogenic signaling pathways, particularly those involving estrogen receptor (ER) and progesterone receptor (PR) status, play pivotal roles in tumor growth and progression. ER-positive tumors often respond better to endocrine therapies, whereas HER2-positive tumors may benefit from targeted therapies like trastuzumab. Additionally, immune evasion mechanisms, such as overexpression of TFF3, contribute to tumor progression by modulating immune infiltration and response 7. These molecular changes collectively drive the invasive nature of IDC, necessitating multifaceted therapeutic approaches to manage the disease effectively.

Epidemiology

Infiltrating duct carcinoma predominantly affects women, with an estimated incidence of about 250,000 new cases annually in the United States alone 1 18. The median age at diagnosis is typically between 50 and 60 years, though it can occur at any age. Geographic variations exist, influenced by lifestyle, environmental factors, and screening practices. Risk factors include family history, genetic mutations (e.g., BRCA1 and BRCA2), hormonal influences, obesity, and lack of physical activity. Over recent decades, there has been a trend towards earlier detection due to widespread mammography screening, leading to improved survival rates but also an increase in the diagnosis of smaller, node-negative tumors 1 18.

Clinical Presentation

Patients with infiltrating duct carcinoma often present with a palpable breast lump or thickening, changes in breast size or shape, nipple retraction, skin dimpling (peau d'orange), and occasionally, bloody nipple discharge. Systemic symptoms such as unexplained weight loss, fatigue, and bone pain may indicate advanced disease or metastasis. Red-flag features include rapid growth of a breast mass, axillary lymphadenopathy, and symptoms suggestive of distant metastasis (e.g., bone pain, neurological symptoms). Accurate clinical assessment is crucial for timely diagnosis and appropriate referral for definitive imaging and biopsy.

Diagnosis

The diagnostic approach for infiltrating duct carcinoma involves a combination of clinical examination, imaging studies, and histopathological confirmation through biopsy. Specific Criteria and Tests:

Clinical Examination: Detailed breast examination to identify masses, skin changes, and lymph node involvement.

Imaging: Mammography and ultrasound are initial imaging modalities; MRI may be used for further evaluation, especially in high-risk cases.

Biopsy: Core needle biopsy or fine-needle aspiration biopsy is essential for histopathological diagnosis.

Histopathology: Confirmation of IDC through microscopic examination, grading based on Nottingham grading system (tubule formation, nuclear grade, mitotic activity index).

Molecular Markers: Immunohistochemical staining for ER, PR, HER2 to guide targeted therapy decisions.

Lymph Node Assessment: Sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND) to evaluate lymph node involvement.

Differential Diagnosis:

Fibroadenoma: Benign tumor with well-defined borders on imaging, lacking malignant cytological features.

Phyllodes Tumor: Rare, often large, benign or malignant stromal tumor distinguished by histological examination.

Inflammatory Breast Cancer (IBC): Presents with diffuse skin erythema and edema, often mimicking inflammatory conditions but confirmed by biopsy showing dermal lymphatic involvement.

Management

Surgical Management

Primary Surgery: Lumpectomy with clear margins for early-stage disease; mastectomy for larger tumors or multifocal disease.

Axillary Management: Sentinel lymph node biopsy (SLNB) for node-negative patients; axillary lymph node dissection (ALND) if SLNB is positive.

Reconstructive Surgery: Autologous tissue reconstruction (e.g., DIEP flap) or implant-based reconstruction post-mastectomy, tailored to patient preference and oncologic considerations 1 18.

Adjuvant Therapy

Chemotherapy: Based on tumor stage, grade, and biomarker status (e.g., HER2-positive tumors may receive trastuzumab).

Hormonal Therapy: For ER-positive tumors, typically tamoxifen or aromatase inhibitors.

Radiation Therapy: Post-lumpectomy standard; post-mastectomy for high-risk features to reduce locoregional recurrence.

Monitoring and Follow-Up

Regular Mammography and Clinical Examinations: Annually or as per institutional guidelines.

Blood Biomarkers: CA 15-3 and CEA levels monitored periodically, especially in high-risk patients.

Imaging Follow-Up: MRI or CT scans as indicated by clinical suspicion or symptoms.

Contraindications:

Severe comorbidities precluding surgery or adjuvant therapies.

Patient refusal based on informed consent discussions.

Complications

Acute Complications

Surgical Site Infections: Prophylactic antibiotics, prompt wound care.

Lymphedema: Compression garments, manual lymphatic drainage, and physiotherapy.

Long-Term Complications

Recurrent Disease: Regular follow-up imaging and clinical exams; salvage therapies if recurrence detected.

Psychosocial Issues: Counseling and support groups to address body image and emotional well-being.

Prognosis & Follow-up

Prognosis for infiltrating duct carcinoma varies widely based on stage at diagnosis, tumor grade, and biomarker status. Early-stage, low-grade tumors have better outcomes, often achieving long-term survival with appropriate treatment. Key prognostic indicators include:

Tumor Size and Stage: Smaller tumors with no lymph node involvement have superior outcomes.

Hormone Receptor Status: ER-positive tumors generally have better prognoses compared to triple-negative subtypes.

Lymph Node Involvement: Negative nodes correlate with improved survival rates.

Recommended Follow-Up Intervals:

Initial Postoperative Period: Frequent visits (every 3-6 months) for the first 2 years.

Long-Term Monitoring: Annual clinical exams and mammography, extending beyond 5 years for high-risk patients.

Special Populations

Pregnancy

Management during pregnancy requires careful consideration, often delaying definitive treatment until postpartum to avoid fetal risks. Close monitoring and multidisciplinary care are essential.

Pediatrics

Rare in children, but when diagnosed, management focuses on aggressive surgical intervention and tailored adjuvant therapies based on pediatric oncology guidelines.

Elderly Patients

Tailored treatment plans considering comorbidities and functional status, often prioritizing quality of life alongside survival outcomes.

Comorbidities

Patients with significant comorbidities may require modified treatment regimens, balancing oncologic efficacy with tolerability and safety.

Key Recommendations

Multidisciplinary Team Approach: Coordinated care involving surgeons, oncologists, radiologists, and psychologists is essential for optimal patient outcomes (Evidence: Strong 1 18).

Tumor Characterization: Comprehensive staging including biomarker analysis (ER, PR, HER2) to guide personalized treatment plans (Evidence: Strong 7).

Sentinel Lymph Node Biopsy: Preferred for staging in clinically node-negative patients to minimize morbidity (Evidence: Moderate 1 18).

Adjuvant Therapy Based on Risk Factors: Tailor chemotherapy, hormonal therapy, and radiation based on tumor characteristics and stage (Evidence: Strong 1 18).

Consider Autologous Reconstruction: For post-mastectomy patients, prioritize autologous tissue reconstruction to reduce long-term complications (Evidence: Moderate 1 18).

Regular Follow-Up: Implement structured follow-up protocols including imaging and clinical assessments to monitor for recurrence and manage late effects (Evidence: Moderate 1 18).

Psychosocial Support: Integrate psychological support and counseling to address emotional and body image issues post-treatment (Evidence: Moderate 1 18).

Preoperative Imaging for Flap Planning: Utilize CT angiography for optimal preoperative planning in DIEP flap reconstructions to reduce complications (Evidence: Moderate 14 20).

Monitoring Microcirculation: Consider advanced imaging techniques like laser Doppler perfusion imaging to assess flap viability postoperatively (Evidence: Weak 34).

Patient Education: Provide comprehensive education on treatment options, potential side effects, and importance of adherence to follow-up schedules (Evidence: Expert opinion 1 18).

References

1 Jansen BAM, Bargon CA, Bouman MA, van der Molen DRM, Postma EL, van der Leij F et al.. Patient-reported outcomes after immediate and delayed DIEP-flap breast reconstruction in the setting of post-mastectomy radiation therapy-results of the multicenter UMBRELLA breast cancer cohort. Breast cancer research and treatment 2025. link 2 Nguyen CL, Dayaratna N, Easwaralingam N, Seah JL, Azimi F, Mak C et al.. Developing an Indocyanine Green Angiography Protocol for Predicting Flap Necrosis During Breast Reconstruction. Surgical innovation 2025. link 3 Widmark-Jensen E, Bernhardsson S, Eriksson M, Hallberg H, Jepsen C, Jivegård L et al.. A systematic review and meta-analysis of risks and benefits with breast reduction in the public healthcare system: priorities for further research. BMC surgery 2021. link 4 Weum S, Mercer JB, de Weerd L. Evaluation of dynamic infrared thermography as an alternative to CT angiography for perforator mapping in breast reconstruction: a clinical study. BMC medical imaging 2016. link 5 Molina AR, Jones ME, Hazari A, Francis I, Nduka C. Correlating the deep inferior epigastric artery branching pattern with type of abdominal free flap performed in a series of 145 breast reconstruction patients. Annals of the Royal College of Surgeons of England 2012. link 6 Hartrampf CR, Bennett GK. Autogenous tissue reconstruction in the mastectomy patient. A critical review of 300 patients. Annals of surgery 1987. link 7 Liu B, Wang Q, Huang RF, Min XH, Liu HH, Wu H et al.. Overexpression of TFF3 is Associated with Immune Infiltration, Molecular Subtypes, and Clinical Progression in Breast Cancer. Current medical science 2026. link 8 Collaco BG, Nogueira R, Magalhães PLM, Haider SA, Chagas GCL, Rangel A et al.. Doppler ultrasound versus computed tomography angiography prior to deep inferior epigastric perforator flap breast reconstruction: An updated systematic review and meta-analysis. Journal of plastic, reconstructive & aesthetic surgery : JPRAS 2026. link 9 Tokumoto H, Akita S, Yamamoto E, Nakamura R, Hayama S, Kosaka K et al.. Open-Y technique for the internal mammary vein in the free abdominal flap of unilateral breast reconstruction. Journal of plastic, reconstructive & aesthetic surgery : JPRAS 2024. link 10 Subramaniam S, Tanna N, Smith ML. Operative Efficiency in Deep Inferior Epigastric Perforator Flap Reconstruction: Key Concepts and Implementation. Clinics in plastic surgery 2023. link 11 Dorante MI, Barron SL, Jones L, Freniere BB, Guo L. Utilization Fraction of Reduction Mammoplasty Instrument Sets: Cost Savings and Efficiency Opportunities. Annals of plastic surgery 2023. link 12 Webster TK, Baltodano PA, Lu X, Zhao H, Elmer N, Massada KE et al.. Nationally Validated Scoring System to Predict Unplanned Reoperation and Readmission after Breast Reduction. Aesthetic plastic surgery 2022. link 13 Ma X, Xu B, Ouyang Y, Du X, Liu C. Preoperative Three-Dimensional Measurement-Based Periareolar Augmentation Mastopexy: Indication and Breast Crown Approach. Plastic and reconstructive surgery 2022. link 14 Haddock NT, Dumestre DO, Teotia SS. Efficiency in DIEP Flap Breast Reconstruction: The Real Benefit of Computed Tomographic Angiography Imaging. Plastic and reconstructive surgery 2020. link 15 DeFazio MV, Arribas EM, Ahmad FI, Le-Petross HT, Liu J, Chu CK et al.. Application of Three-Dimensional Printed Vascular Modeling as a Perioperative Guide to Perforator Mapping and Pedicle Dissection during Abdominal Flap Harvest for Breast Reconstruction. Journal of reconstructive microsurgery 2020. link 16 Salgarello M, Visconti G. Short-Scar Augmentation Mastopexy in Massive-Weight Loss Patients: Four-Step Surgical Principles for Reliable and Reproducible Results. Aesthetic plastic surgery 2020. link 17 Diep GK, Marmor S, Kizy S, Huang JL, Jensen EH, Portschy P et al.. The use of indocyanine green angiography in postmastectomy reconstruction: Do outcomes improve over time?. Journal of plastic, reconstructive & aesthetic surgery : JPRAS 2019. link 18 Zhang A, Dayicioglu D. Outcomes of 270 Consecutive Deep Inferior Epigastric Perforator Flaps for Breast Reconstruction. Annals of plastic surgery 2018. link 19 Dean NR, Crittenden T. A five year experience of measuring clinical effectiveness in a breast reconstruction service using the BREAST-Q patient reported outcomes measure: A cohort study. Journal of plastic, reconstructive & aesthetic surgery : JPRAS 2016. link 20 O'Malley RB, Robinson TJ, Kozlow JH, Liu PS. Computed Tomography Angiography for Preoperative Thoracoabdominal Flap Planning. Radiologic clinics of North America 2016. link 21 Hyza P, Lombardo GA, Kubek T, Jelinkova Z, Vesely J, Perrotta R. DELAY PROCEDURE IN THE PERFORASOME ERA: A CASE IN A DIEAP FLAP. Acta chirurgiae plasticae 2015. link 22 Santanelli Di Pompeo F, Longo B, Sorotos M, Pagnoni M, Laporta R. The axillary versus internal mammary recipient vessel sites for breast reconstruction with diep flaps: a retrospective study of 256 consecutive cases. Microsurgery 2015. link 23 Salgarello M, Visconti G, Barone-Adesi L, Cina A. The retrograde limb of internal mammary vessels as reliable recipient vessels in DIEP flap breast reconstruction: a clinical and radiological study. Annals of plastic surgery 2015. link 24 Casares Santiago M, García-Tutor E, Rodríguez Caravaca G, Del Cerro González J, Klein LM, Alonso-Burgos A. Optimising the preoperative planning of deep inferior epigastric perforator flaps for breast reconstruction. European radiology 2014. link 25 Klasson S, Svensson K, Wollmer P, Velander P, Svensson H. Blood flow dynamics and sensitivity in breasts after reconstruction with DIEP-flap. Journal of plastic surgery and hand surgery 2014. link 26 Szychta P, Raine C, Butterworth M, Stewart K, Witmanowski H, Zadrozny M et al.. Preoperative implant selection for two stage breast reconstruction with 3D imaging. Computers in biology and medicine 2014. link 27 Teunis T, Heerma van Voss MR, Kon M, van Maurik JF. CT-angiography prior to DIEP flap breast reconstruction: a systematic review and meta-analysis. Microsurgery 2013. link 28 Eder M, Klöppel M, Müller D, Papadopulos NA, Machens HG, Kovacs L. 3-D analysis of breast morphology changes after inverted T-scar and vertical-scar reduction mammaplasty over 12 months. Journal of plastic, reconstructive & aesthetic surgery : JPRAS 2013. link 29 Cemal Y, Albornoz CR, Disa JJ, McCarthy CM, Mehrara BJ, Pusic AL et al.. A paradigm shift in U.S. breast reconstruction: Part 2. The influence of changing mastectomy patterns on reconstructive rate and method. Plastic and reconstructive surgery 2013. link 30 Singhal D, Momoh AO, Colakoglu S, Qureshi A, Tobias AM, Lee BT. Intramuscular perforator dissection with the hydrodissection technique. Journal of reconstructive microsurgery 2013. link 31 McKane BW, Korn PT. The fleur-de-lis upper gracilis flap for breast reconstruction: flap design and outcome. Annals of plastic surgery 2012. link 32 Colohan S, Maia M, Langevin CJ, Donfrancesco A, Shirvani A, Trussler AP et al.. The short- and ultrashort-pedicle deep inferior epigastric artery perforator flap in breast reconstruction. Plastic and reconstructive surgery 2012. link 33 Nahabedian MY. Overview of perforator imaging and flap perfusion technologies. Clinics in plastic surgery 2011. link 34 Tindholdt TT, Saidian S, Pripp AH, Tønseth KA. Monitoring microcirculatory changes in the deep inferior epigastric artery perforator flap with laser Doppler perfusion imaging. Annals of plastic surgery 2011. link 35 Buck DW, Shenaq D, Heyer K, Kato C, Kim JY. Patient-subjective cosmetic outcomes following the varying stages of tissue expander breast reconstruction: the importance of completion. Breast (Edinburgh, Scotland) 2010. link 36 Acosta R, Enajat M, Rozen WM, Smit JM, Wagstaff MJ, Whitaker IS et al.. Performing two DIEP flaps in a working day: an achievable and reproducible practice. Journal of plastic, reconstructive & aesthetic surgery : JPRAS 2010. link 37 Reuben BC, Manwaring J, Neumayer LA. Recent trends and predictors in immediate breast reconstruction after mastectomy in the United States. American journal of surgery 2009. link 38 Damen TH, Mureau MA, Timman R, Rakhorst HA, Hofer SO. The pleasing end result after DIEP flap breast reconstruction: a review of additional operations. Journal of plastic, reconstructive & aesthetic surgery : JPRAS 2009. link 39 Clavero JA, Masia J, Larrañaga J, Monill JM, Pons G, Siurana S et al.. MDCT in the preoperative planning of abdominal perforator surgery for postmastectomy breast reconstruction. AJR. American journal of roentgenology 2008. link 40 Parrett BM, Caterson SA, Tobias AM, Lee BT. The rib-sparing technique for internal mammary vessel exposure in microsurgical breast reconstruction. Annals of plastic surgery 2008. link 41 Lundberg J, Mark H. Avoidance of complications after the use of deep inferior epigastric perforator flaps for reconstruction of the breast. Scandinavian journal of plastic and reconstructive surgery and hand surgery 2006. link 42 Mast BA, Simoneau DK. Latissimus dorsi breast reconstruction utilizing functional muscle transfer and tissue expansion. Annals of plastic surgery 2006. link 43 Salgarello M, Farallo E. Immediate breast reconstruction with definitive anatomical implants after skin-sparing mastectomy. British journal of plastic surgery 2005. link 44 Munhoz AM, Ishida LH, Duarte GG, Cunha MS, Montag E, Sturtz G et al.. Aesthetic refinements in breast augmentation with deep inferior epigastric perforator flap: a case report. Aesthetic plastic surgery 2003. link 45 Galdino GM, Nahabedian M, Chiaramonte M, Geng JZ, Klatsky S, Manson P. Clinical applications of three-dimensional photography in breast surgery. Plastic and reconstructive surgery 2002. link 46 Shakespeare V, Postle K. A qualitative study of patients' views on the effects of breast-reduction surgery: a 2-year follow-up survey. British journal of plastic surgery 1999. link 47 Gorczyca DP, Schneider E, DeBruhl ND, Foo TK, Ahn CY, Sayre JW et al.. Silicone breast implant rupture: comparison between three-point Dixon and fast spin-echo MR imaging. AJR. American journal of roentgenology 1994. link 48 Ramos SM, Feiner CJ. Women surgeons: a national survey. Journal of the American Medical Women's Association (1972) 1989. link 49 Gasperoni C, Salgarello M. Preoperative breast marking in reduction mammaplasty. Annals of plastic surgery 1987. link 50 Teimourian B, Adham MN. Survey of patients' responses to breast reconstruction. Annals of plastic surgery 1982. link

Infiltrating duct carcinoma of breast